

Anticoagulants Market Is Estimated To Be Worth US\$ 65 Bn by 2031, Expanding At An 8.04 % CAGR During The Forecast Period

Anticoagulants Market is projected to trace a healthy growth trajectory, and grow ~1.6X during 2021-2031

UNITED STATES, December 24, 2021 /EINPresswire.com/ -- The popularity of online pharmacies is growing at an unprecedented rate in the anticoagulants market, and these channels are projected to emerge as the standard distribution channel in the future. A rapid rise in sales from these channels is also attributable to the increasing [demand for effective anticoagulant drugs](#) in developing countries, which is influencing players in the anticoagulants market to target untapped countries with minimal investments in distribution establishments. However, frequent instances of patent expiry are offering a leeway to generic drugs, which is projected to impede the advancement of the anticoagulants market during the forecast period (2020-2026).

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=4335

The aforementioned insights are explored comprehensively, along with accurate data, in an exclusive study published by Fact.MR. According to the report, the anticoagulants market is projected to trace a healthy growth trajectory, and grow ~1.6X during 2020-2026.

Key Takeaways of Anticoagulants Market Study

The cost-effective attribute of conventional drugs, such as warfarin, is boosting consumers' loyalty towards these drugs, thereby limiting the opportunities for anticoagulants.

Producers are leveraging the prowess of quality development by zooming in their focus on the development of products with fewer to nil side effects, as anticoagulants are found to have caused nausea, vomiting, and excessive bleeding in some patients.

The introduction of patient-assistance programs by leading players to cushion the high finances required for the production of anticoagulant drugs is expected to serve as an instrument to strategize customer acquisition and retention. Daiichi Sankyo—a leading player in the anticoagulants market—illustrates this strategy. The company offers the SAVAYSA Savings Card to eligible patients at US\$ 4 for a 30-day prescription, and US\$ 12 for a 90-day prescription.

Competitive Landscape

The anticoagulants landscape is competitive and fragmented, with numerous significant competitors. As a tool to increase anticoagulant exposure, players in the anticoagulants industry are stepping forward to carry the financial burden of individuals through patient-assistance programmes.

- In August 2020, Bristol-Myers Squibb, in alliance with Pfizer, announced that the U.S District Court upheld their composition of matter (COP) patent (US 6,967,208) and formulation patent (US 9,326,945) covering their Eliquis® Apixaban anticoagulants.
- Likewise, in November 2020, Boehringer Ingelheim received approval from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) for the use of Pradaxa® (dabigatran etexilate) for treating venous thromboembolic events and preventing its recurrence in pediatric patients below 18 years

Need more information about Report Methodology? Click here-
https://www.factmr.com/connectus/sample?flag=RM&rep_id=4335

The oral route of drug administration remains the standard method, with an estimated share of ~54% in 2020, in the anticoagulants market. Concerns regarding the sterilization of needles leading to contagious diseases and infections are offering an edge to the oral consumption of drugs.

Factor XA Inhibitors accounted for ~50% share in the anticoagulants market in 2019, and are likely to retain their dominance in the drug class during 2020-2026. These drugs do not have any food interactions, owing to minimal metabolism through the CYP450 system.

“Untapped markets with high RoI potential in the anticoagulants market—India, China, South Africa, Mexico, and Brazil—are worth exploring to reduce overhead cost, and, in turn, gain a price competitive advantage without squeezing profit margins”, recommends a seasoned analyst at Fact.MR.

Market Majors Develop Blockbuster Drugs; Local Players Rely on Generic Drugs

Despite the growing popularity of blockbuster drugs, the threat of patent expiration is a cause of high concern among players in the anticoagulants market, which necessitates efforts and capital in research & development activities. The introduction of effective drugs remains the key strategy of leading players particularly, as the production of generic drugs by local and regional players hard-hits the revenue of these players. A leading player, Boehringer Ingelheim GmbH, announced the launch of a research & development program to explore its capabilities, increase number of pipeline drugs, and, in turn, collaborate with external partners. However, as novel drugs are cost-prohibitive in nature, small- and mid-level players are expanding in the anticoagulants market through the introduction of generic drugs.

Key Segments Covered

Drug Class

- Factor X Inhibitor (NOAC/DOAC) Anticoagulants
- Heparin Anticoagulants

- Direct Thrombin Inhibitor Anticoagulants
- Vitamin K Antagonist Anticoagulants

Indication

- Anticoagulants for Deep Vein Thrombosis
- Anticoagulants for Pulmonary Embolism
- Anticoagulants for Atrial Fibrillation & Heart Attack
- Anticoagulants for Other Indications

Route of Administration

- Oral Anticoagulants
- Injectable Anticoagulants

Distribution Channel

- Anticoagulants Sales via Hospital Pharmacies
- Anticoagulants Sales via Retail Pharmacies
- Anticoagulants Sales via Online Pharmacies

Full Access of this Exclusive Report is Available at- <https://www.factmr.com/checkout/4335>

Find More Valuable Insights on Anticoagulants Market

Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global anticoagulants market, presenting historical demand data (2016-2019), and forecast statistics for the period of 2020-2026. The study divulges compelling insights on the anticoagulants market on the basis of Drug Class (Factor XA Inhibitors (NOAC/DOAC), Heparins, Direct Thrombin Inhibitors, and Vitamin K Antagonists), Indication (Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation & Heart Attack, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Route of Administration (Oral and Injectable), across five major regions.

About Fact.MR

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we'll be an able research partner.

Contact:

US Sales Office:

11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: <https://www.factmr.com>

Supriya Bhor
EMINENT RESEARCH & ADVISORY SERVICES
+91 9922699448
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/559111446>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.